Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses. The Company’s technologies include HemeScreen and IV-Cell. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its technology enables testing to be completed in one rapid scanning process. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
Símbolo de cotizaciónPRPO
Nombre de la empresaPrecipio Inc
Fecha de salida a bolsaJul 18, 2000
Director ejecutivoMr. Ilan Danieli
Número de empleados54
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 18
Dirección4 Science Park
CiudadNEW HAVEN
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal06511
Teléfono12037877888
Sitio Webhttps://www.precipiodx.com/
Símbolo de cotizaciónPRPO
Fecha de salida a bolsaJul 18, 2000
Director ejecutivoMr. Ilan Danieli
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos